US based COBRA diagnostic prostate cancer trial reaches recruitment target
- Written by PR Newswire
![]() |
SYDNEY, Feb. 9, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce its diagnostic 64Cu SAR-bisPSMA trial COBRA (NCT05249127)1 for patients...
Read more: US based COBRA diagnostic prostate cancer trial reaches recruitment target